Hot topics at ASCO 2020
Novel checkpoints, the BCMA race and first-in-human data from novel platforms will be center stage at ASCO
Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update.
Areas to watch include next-generation checkpoint targets, where data from an anti-TIGIT antibody are breathing new life into a stalled target space, and the anti-BCMA landscape for multiple myeloma (MM), where a timely regulatory announcement led to a major shakeup in the tight race to market.
Also on the docket are first-in-human trials of platform technologies where early proof-of-concept signals could trigger a flood of interest and investment.
The 2020 ASCO Virtual Scientific Program will run May 29-31. The bulk of the abstracts were released last week, but many companies will present additional data next week that look beyond the abstract data cutoffs in January and February.
Some of the targets, modalities and therapeutic areas featured at this year’s conference -- such as BCMA and bispecific antibodies -- reflect building of the themes present last year (see “ASCO 2019 Abstracts Show Solid Tumor Race Heating Up”).
Others reflect early-stage hot topics BioCentury has been following as they transition to the clinic, including targeted degraders, myeloid mechanisms and